2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Montanari F, Deng C, Sawas A, Lue J, Marchi E, Radeski D, Cheng B, Bhagat G, O'Connor O. Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood 2019, 134: 2909. DOI: 10.1182/blood-2019-131841.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderDiffuse large B-cell lymphomaMonomorphic post-transplant lymphoproliferative disorderProgression-free survivalMedian progression-free survivalOverall survivalR-CHOPR-EPOCHGerminal centersCell of originImmunosuppressive therapyEBV infectionLymphoproliferative disordersTerms of PFSBetter progression-free survivalDLBCL subtypesCommon first-line therapySeattle GeneticsDiffuse large B-cell lymphoma (DLBCL) subtypeLarge B-cell lymphomaMonths-24 yearsComplete response rateMedian overall survivalPrimary refractory diseaseFirst-line therapy
2014
The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)
Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderProgression-free survivalProlonged progression-free survivalCell of originAdvanced stage diseaseExtra-nodal involvementPrimary refractory diseaseFirst-line therapyR-CHOPR-EPOCHOverall survivalRituximab monotherapyLine therapyNodal involvementRefractory diseaseStage diseaseClinical presentationLymphoproliferative disordersTreatment regimensB cellsBone marrow/stem cell transplantationAutologous stem cell transplantCommon first-line therapyNon-germinal center B-cell
2010
T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant.
Montanari F, Bhagat G, Zain J, Seshan V, Magid Diefenbach C, Clark-Garvey S, McCormick E, Crook M, Conroy M, O'Connor O. T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant. Journal Of Clinical Oncology 2010, 28: 8056-8056. DOI: 10.1200/jco.2010.28.15_suppl.8056.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderClinical characteristicsSerious complicationsLymphoproliferative disordersPrognostic assessmentComplicationsTransplant